Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegcrisantaspase - Jazz Pharmaceuticals Inc

Next Previous
Drug Profile

Pegcrisantaspase - Jazz Pharmaceuticals Inc

Alternative Names: Asparec; JZP-416; mPEG-R-crisantaspase; PEG-crisantaspase; Pegylated-crisantaspase; PEGylated-Erwinia-chrysanthemi-L-asparaginase; Polyethylene-glycol-Erwinia-chrisanthemi-L-asparaginase

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alize Pharma II SAS
  • Developer EUSA Pharma; Jazz Pharmaceuticals Inc
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Amidohydrolase stimulants; Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Acute myeloid leukaemia
  • No development reported Haematological malignancies

Most Recent Events

  • 09 Dec 2023 Final efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 28 Aug 2020 M.D. Anderson Cancer Center and National Cancer Institute plans a phase I trial for Leukemia (Second line therapy or greater) in USA (NCT04526795)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Haematological-malignancies(Second-line therapy or greater) in France (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top